All News

pso.PsA_.NPF_.jpg

Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis

Jack Cush, MD

The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.

Read Article
pregnant-776506__180.jpg

PIANO Study - Safety of Biologics in Pregnancy

Jack Cush, MD

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
ACR20 Podcast

ACR20 - Autoinflammatory & Still's Disease Panel

Jack Cush, MD

This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.

Read Article
podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
influenza-156098_640.png

Flu and Tofacitinib

Kathryn H. Dao, M.D.

Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.

Read Article
ACR Mon

ACR20 - Day 4 Report

Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis #ACR20 https://t.co/uE4ZmfulbP https://t.co/OzpX6hLw6O

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our latest. PIANO Study - Safety of Biologics in Pregnancy https://t.co/XskLByJZ9n https://t.co/JBHKo0T0jX

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : Wonder if you can predict which pts you can taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26); low Doppler serum score for 24 jts predicted discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. https://t.co/6hv5M1CQwT
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway : Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/6fQNzqsvby

Links:

Dr. John Cush RheumNow ( View Tweet)

(if this is true) Shame on @expressScripts and forcing money driven biologic changes (from secukinumab to ixekizumab) upon patients and doctors. This is soooo wrong! https://t.co/DYKSItCbYL

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @MeralElRamahiMD :Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @ElaineHusniMD https://t.co/tCAbgYi3h0 https://t.co/AoEOJd3pQh

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms #ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/Bm5rgBPKkH

Links:

Dr. John Cush RheumNow ( View Tweet)
Read more on Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis by Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/yataL7H8X4 https://t.co/JBM8V6OX8J

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
sheila RHEUMarampa ( View Tweet)
#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow https://t.co/H9rgSxL6VP
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×